Systemic Cancer Therapies
Immunotherapy
Immunotherapy
Cutting-edge biological therapies utilizing immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, CTLA-4) to empower the patient’s own immune system to identify, target, and destroy cancer cells.
Immunotherapy represents a transformative paradigm in modern medical oncology. Rather than attacking cancer cells directly with cytotoxic agents, it re-activates the patient’s intrinsic immune machinery to overcome tumor-induced immunosuppression.
Indications & Approaches:
- Immune Checkpoint Inhibitors: Monoclonal antibodies targeting PD-1 (Pembrolizumab, Nivolumab), PD-L1 (Atezolizumab, Durvalumab), and CTLA-4 (Ipilimumab).
- Biomarker-Driven Selection: Comprehensive testing for PD-L1 TPS/CPS scores, Microsatellite Instability (MSI-H / dMMR), and Tumor Mutational Burden (TMB).
- Synergistic Combination Regimens: Chemo-immunotherapy protocols delivering superior progression-free and overall survival rates.
- Immune-Related Adverse Event (irAE) Management: Specialized clinical surveillance and early intervention for immune-mediated toxicities.
Consultation with Dr. Chinmayee Agrawal
ECMO Certified Medical Oncologist • Sarvodaya Hospital (Greater Noida West) • Sri Balaji Hospital (Ludhiana)